These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 9617787)

  • 61. DopAmide: Novel, Water-Soluble, Slow-Release l-dihydroxyphenylalanine (l-DOPA) Precursor Moderates l-DOPA Conversion to Dopamine and Generates a Sustained Level of Dopamine at Dopaminergic Neurons.
    Atlas D
    CNS Neurosci Ther; 2016 Jun; 22(6):461-7. PubMed ID: 26861609
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Oxidative metabolites of 5-S-cysteinyldopamine inhibit the pyruvate dehydrogenase complex.
    Li H; Dryhurst G
    J Neural Transm (Vienna); 2001; 108(12):1363-74. PubMed ID: 11810401
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Iron- and manganese-catalyzed autoxidation of dopamine in the presence of L-cysteine: possible insights into iron- and manganese-mediated dopaminergic neurotoxicity.
    Shen XM; Dryhurst G
    Chem Res Toxicol; 1998 Jul; 11(7):824-37. PubMed ID: 9671546
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Continuous covariability of dopamine and serotonin metabolites in human cerebrospinal fluid.
    Geracioti TD; Keck PE; Ekhator NN; West SA; Baker DG; Hill KK; Bruce AB; Wortman MD
    Biol Psychiatry; 1998 Aug; 44(3):228-33. PubMed ID: 9693394
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Manganese increases L-DOPA auto-oxidation in the striatum of the freely moving rat: potential implications to L-DOPA long-term therapy of Parkinson's disease.
    Serra PA; Esposito G; Enrico P; Mura MA; Migheli R; Delogu MR; Miele M; Desole MS; Grella G; Miele E
    Br J Pharmacol; 2000 Jun; 130(4):937-45. PubMed ID: 10864903
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Brain dopamine turnover and the relief of parkinsonism.
    Rinne UK; Sonninen V; Marttila R
    Adv Exp Med Biol; 1977; 90():267-75. PubMed ID: 930747
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Correlation of clinical symptoms, HVA and 5-HIAA in csf and plasma L-DOPA in Parkinsonian patients treated with L-DOPA and L-DOPA + RO 4-4602.
    Campanella G; Algeri S; Cerletti C; Dolfini E; Jori A; Rinaldi F
    Eur J Clin Pharmacol; 1977 Apr; 11(4):255-61. PubMed ID: 862646
    [No Abstract]   [Full Text] [Related]  

  • 68. Neurochemical markers in the cerebrospinal fluid of patients with Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis and normal controls.
    Hartikainen P; Reinikainen KJ; Soininen H; Sirviö J; Soikkeli R; Riekkinen PJ
    J Neural Transm Park Dis Dement Sect; 1992; 4(1):53-68. PubMed ID: 1347220
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Cerebrospinal fluid levels of alpha-tocopherol (vitamin E) in Parkinson's disease.
    Molina JA; de Bustos F; Jiménez-Jiménez FJ; Benito-León J; Ortí-Pareja M; Gasalla T; Tallón-Barranco A; Navarro JA; Arenas J; Enríquez-de-Salamanca R
    J Neural Transm (Vienna); 1997; 104(11-12):1287-93. PubMed ID: 9503274
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Biochemical diagnosis of dopaminergic disturbances in paediatric patients: analysis of cerebrospinal fluid homovanillic acid and other biogenic amines.
    Marín-Valencia I; Serrano M; Ormazabal A; Pérez-Dueñas B; García-Cazorla A; Campistol J; Artuch R
    Clin Biochem; 2008 Nov; 41(16-17):1306-15. PubMed ID: 18790694
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Decreased cerebrospinal fluid levels of neutral and basic amino acids in patients with Parkinson's disease.
    Molina JA; Jiménez-Jiménez FJ; Gomez P; Vargas C; Navarro JA; Ortí-Pareja M; Gasalla T; Benito-León J; Bermejo F; Arenas J
    J Neurol Sci; 1997 Sep; 150(2):123-7. PubMed ID: 9268238
    [TBL] [Abstract][Full Text] [Related]  

  • 72. [Concentrations of monoamines and monoamine metabolites in cerebrospinal fluid determined by high-performance liquid chromatography with electrochemical detection].
    Yoshino K
    No To Shinkei; 1982 Nov; 34(11):1099-106. PubMed ID: 6186264
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Parkinson's disease and amine metabolites in cerebrospinal fluid: implications for L-Dopa therapy.
    Korf J; van Praag HM; Schut D; Nienhuis RJ; Lakke JP
    Eur Neurol; 1974; 12(5-6):340-50. PubMed ID: 4448192
    [No Abstract]   [Full Text] [Related]  

  • 74. MitoPark mice mirror the slow progression of key symptoms and L-DOPA response in Parkinson's disease.
    Galter D; Pernold K; Yoshitake T; Lindqvist E; Hoffer B; Kehr J; Larsson NG; Olson L
    Genes Brain Behav; 2010 Mar; 9(2):173-81. PubMed ID: 20002202
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Four pioneers of L-dopa treatment: Arvid Carlsson, Oleh Hornykiewicz, George Cotzias, and Melvin Yahr.
    Lees AJ; Tolosa E; Olanow CW
    Mov Disord; 2015 Jan; 30(1):19-36. PubMed ID: 25488030
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Serotonergic markers in Parkinson's disease and levodopa-induced dyskinesias.
    Cheshire P; Ayton S; Bertram KL; Ling H; Li A; McLean C; Halliday GM; O'Sullivan SS; Revesz T; Finkelstein DI; Storey E; Williams DR
    Mov Disord; 2015 May; 30(6):796-804. PubMed ID: 25649148
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Failure of cerebrospinal fluid homovanillic acid to predict levodopa response in Parkinson's disease.
    Weiner WJ; Klawans HL
    J Neurol Neurosurg Psychiatry; 1973 Oct; 36(5):747-52. PubMed ID: 4753871
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Comparative analysis of indices of central dopaminergic functions in man.
    Bagdy G; Arató M; Baraczka K; Fekete MI
    Life Sci; 1983 Jun; 32(23):2667-76. PubMed ID: 6855463
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Susceptibility to neuroleptic malignant syndrome in Parkinson's disease.
    Ueda M; Hamamoto M; Nagayama H; Otsubo K; Nito C; Miyazaki T; Terashi A; Katayama Y
    Neurology; 1999 Mar; 52(4):777-81. PubMed ID: 10078727
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Cerebrospinal fluid homovanillic acid and parkinsonism in Huntington's disease.
    Kurlan R; Goldblatt D; Zaczek R; Jeffries K; Irvine C; Coyle J; Shoulson I
    Ann Neurol; 1988 Aug; 24(2):282-4. PubMed ID: 2972251
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.